NCT01498887 - Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy | Biotech Hunter

Enrollment

347

Participants

Timeline

Start Date

December 24, 2011

Primary Completion Date

December 26, 2015

Study Completion Date

December 26, 2015

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod (FTY720)

Hard gelatin capsules containing 0.5 mg of fingolimod.

Trial Locations (47)

2050

Novartis Investigative Site, Sydney

2170

Novartis Investigative Site, Liverpool

2250

Novartis Investigative Site, East Gosford

2259

Novartis Investigative Site, Kanwal

2305

Novartis Investigative Site, New Lambton Heights

3000

Novartis Investigative Site, Melbourne

3011

Novartis Investigative Site, Fitzroy

3050

Novartis Investigative Site, Parkville

3128

Novartis Investigative Site, Box Hill

3220

Novartis Investigative Site, Geelong VIC

4029

Novartis Investigative Site, Brisbane Queensland

4066

Novartis Investigative Site, Auchenflower

6009

Novartis Investigative Site, Nedlands

14004

Novartis Investigative Site, Córdoba

15006

Novartis Investigative Site, A Coruña

15405

Novartis Investigative Site, Ferrol

18012

Novartis Investigative Site, Granada